Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
Status:
Completed
Trial end date:
2021-02-12
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label clinical study to study the efficacy of apremilast in the
treatment of mild to moderate central centrifugal cicatricial alopecia. The investigators
hypothesize that the anti-inflammatory properties of apremilast may play a role in the
decreasing scalp inflammation in patients with CCCA and may prevent further hair loss and
potentially induce hair regrowth in patients with mild to moderate disease.